HBV Dna Level at 24 Weeks is the Best Predictor of Virological Response to Adefovir Add-On Therapy in Patients with Lamivudine Resistance

Abstract

Although the HBV DNA level at baseline is often used to predict the antiviral potency of lamivudine and adefovir combination treatment in CHB patients with lamivudine resistance, the results of this study suggest that the HBV DNA level at 24 weeks is a better marker for the virological response.